“I always say it's very easy to identify problems. It's not so easy to come up with the solutions or even the right solution. And that's really what we try to do on a daily basis here.” - Jay S. Duker, M.D., $EYPT President and CEO. Hear more below on our innovation and

Our company culture stems from our team at #EYPT. They are our greatest strength, and their determination and collaboration foster an environment of innovation.

We are pleased to share two significant milestones in our global pivotal Ph 3 wet AMD program:. 1️⃣First patient outside of the U.S. has been dosed in our Ph 3 LUCIA trial.2️⃣Received approval for our Ph 3 trial protocol in Europe, underscoring strategic & thoughtful trial design.

Our $EYPT team is gearing up for the Goldman Sachs 46th Annual Global Healthcare Conference, next week. Looking forward to connecting with the investor community at this event!

Please join us in welcoming our Summer 2025 intern class at $EYPT!. We look forward to working with each of our new interns, providing them with first-hand experience and opportunities. #FormulateYourFuture

#TOMORROW $EYPT we will be attending the Jefferies Global Healthcare Conference in the big🍎. Looking forward to sharing more about our ongoing #ClinicalTrials and connecting with other leaders in the healthcare industry!

We are proud to share that #EYPT has renewed our sponsorship for the American College of Eye Technicians (ACET), underscoring our commitment to this non-profit organization helping to educate, train and then place graduates at ophthalmology practices.

Our $EYPT team is gearing up for next month and looking forward to sharing more on our innovative #RetinaPipeline at upcoming conferences.

#ICYMI We announced our pivotal Phase 3 LUGANO trial in wet AMD has been fully enrolled & randomized in seven months! This milestone couldn't have been accomplished without the support, dedication & hard work from the investigators and study coordinators involved in this trial.

✅ 400+ patients enrolled & randomized in 7 months .1️⃣ First pivotal trial in global Phase 3 program .📈 Topline data expected mid-2026 . 👉 Check out more on our latest milestone and what’s next for LUCIA here:

Wet AMD can cause irreversible vision loss, and patients face a high treatment burden, often leading to missed appointments. This #HealthyVisionMonth, we’re advancing our Phase 3 #WetAMD program and are proud to partner with @FightBlindness in the fight against #RetinalDiseases.

Our end goal: to help patients, practitioners, and families. Learn more about our pipeline progress here:

Tomorrow, $EYPT EVP & CFO, George Elston, will be in New York City at the RBC Capital Markets Global Healthcare Conference to share more about our ongoing pivotal Phase 3 clinical trials.

$EYPT will be in New York City next week for the @MizuhoAmericas Neuro & Ophthalmology Summit. As we continue to advance our #Retina pipeline, we look forward to connecting with fellow business leaders who are shaping the future of eye care.

✈️ $EYPT is en route to the @RCOphth Congress for #EyeConUK in Liverpool. Our team is looking forward to presenting the results from our Phase 2 DAVIO 2 #WetAMD clinical trial. Stop by to check it out!

It’s been an exciting couple of weeks engaging in discussions with global #Retina leaders at ARVO, Retina World Congress and #FSO2025. Thank you to everyone who attended our presentations.

Partnerships with nonprofits like @CarrollCenter inspire our work. At our recent Lunch & Learn, they showed how purpose goes both ways. We’re proud to support their mission and the Walk for Independence on May 31! Learn more:

Onsite at #SFO2025 in Paris, France? Don’t miss a presentation of results from the Phase 2 DAVIO 2 #WetAMD clinical trial.

#InvestorNews: $EYPT reports Q1 2025 financial results.

We’re attending this year’s @RetinaWCongress to discuss our recent progress for our pivotal Phase 3 clinical trials and engage in discussions on the future of #Retina. Stop by our corporate presentation and booth #21 to learn more. #RetinaWorldCongress